SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.